Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Further analysis of data from the Gemini study, the first to be reported with Caduet (Pfizer, New York, NY), a single fixed-dose combination pill containing the calcium channel blocker amlodipine ...
The LIBERTY-CUPID C study enrolled CSU patients aged six years and older who remained symptomatic despite standard-of-care (SOC) antihistamines and were not previously treated with Novartis ...
AstraZeneca AZN has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap (capivasertib) in certain patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results